_tif.png)
OMR
Order-made Medical Research Inc.
Make the impossible possible for Therapeutic Antibody
About Us
Order-made Medical Research Inc. (OMR) is a biotech company promoting technology development that revolutionize therapeutic antibodies.
We have made it possible to generate prominent antibodies against multi-transmembrane target molecules that have been difficult to create and have succeeded in expanding the number of target molecules extremely for therapeutic antibodies. Furthermore, as a further application development, we are challenging to create innovative therapeutic antibodies targeted intracellular molecules and disease-specific immunogenicity changes that have been difficult to target antibodies.
We will pursue business to explore target molecules for therapeutic antibodies and generate them to out-license them to pharmaceuticals and biotech companies at the early stages of R&D.
SARS-CoV-2 Antibody Test
We provide quantitative testing for SARS-CoV-2 antibodies
Inquiries and Applications : kotai-kensa@omr.co.jp
For more information about this service, please also see the following link.
2024年12月27日(金)をもってお申込みの受付を終了させていただきます。
ご希望の方はお早目にご連絡ください。
This service can be used to determine antibody levels before and after SARS-CoV-2 vaccination.
For inquiries and applications, please contact us at the e-mail address below.
(This service is only accessible by the following e-mail address.)
<Caution> This service is provided only in Japan. Applications from overseas are not accepted.
News
Our Technology
Proprietary innovative antibody
generating technology
We have established " LIMAXYS ™ ", an innovative antibody generating technology using metastatic cancer cell properties and made it possible to generate prominent antibodies against multi-transmembrane target molecules that have been difficult to create. This makes it possible to generate approximately 5,600 antibodies for all of membrane proteins theoretically.
Furthermore, we are working on to establish " INTAB ™ " internalization antibodies technologies targeting intracellular molecules, and " MUTAB ™ " selective antibody technologies recognizing disease specific immunogenicity changes associated with genetic mutations, post-translational modifications and others.
By applying various modalities (new therapeutic approach) with diversified partners, it makes possible to develop and provide therapeutic antibodies for difficult cancer types to treat, which showing multiple phenotypes, including drug resistance, immunological escaping and cancer stem cells, and for refractory autoimmune diseases, neurodegenerative diseases and so on, that is expected to cause a substantial paradigm shift in future medical care.
Antibody Engineering
LIMAXYS™️
Immunization by target molecule expressed metastatic tumor cell (genetically modified) transplantation
Extra Cellular Domain Antibody
Target molecules and potential Applications (modalities)
Transmembrane molecules
-
Agonistic antibodies
-
Cell-functional modified antibodies
-
Immuno-redirected Bi-Specific Antibodies
Bioinformatics
INTAB™️
Immunization through epitope prediction via amino acid sequence and 3D structure
Internalization antibody
Target molecules and potential Applications (modalities)
Intracellular molecules
-
Payload Conjugated Antibodies:
-
ASO, siRNA, miRNA
-
Radio Active
-
Drug
-
-
Drug Delivery System
-
Intracellular multi-Specific Antibodies
Immuno-Genomics
MUTAB™️
Immunization with targeting disease specific immunogenicity change
Disease Specified Selective Antibody
Target molecules and potential Applications (modalities)
Genetic mutation and immunogenicity
-
Hi Affinity and Tissue - Selectivity
-
ADCC/CDC Antibodies
-
CAR-T, TCR-T（MHC-Ag CAR-T)
Introduction of Founder
Yasufumi Murakami
President and CEO
Dr. Murakami is a founder and CEO of OMR. Research Fellow at Alberta Einstein Medical University, Immunology, Sloan-Kettering Commemorative Cancer Research Center, Molecular Biology and Virology Division. After engaging in research on antibody and genomic biology at RIKEN, he became professor of the Department of Biological Engineering at Tokyo University of Science and also served as a visiting professor at Tottori University, founded OMR in 2012. Graduated doctoral course at University of Tokyo (Pharmaceutical Science). Specialty fields are therapeutic antibody, genomic biology, genetic engineering.
Access
Order-made Medical Research Inc.
5-5-4, Tokodai, Tsukuba-shi, Ibaraki 300-2635 JAPAN
By train
1. Get off at Kenkyū-gakuen Station on the Tsukuba Express Line.
2. It takes about 7 minites by cab from the north exit of the station.
By car
-
It is about 8 km from the Yatabe Interchange on the Joban Expressway toward Tsukuba. When coming from the Ken-O Expressway, it is about 4 km from the Tsukuba-chuo Interchange in the direction of Tsukuba Science City.
-
At the Omonoidai intersection, go toward Tokodai kenkyu danchi and turn left before ZOZOBASE Tsukuba 1.
-
Go straight for about 200 meters and our company is located at the left end of the lot on the left side.
Contact
Inquiries about our technology and products are accepted here. Please contact us by telephone, fax, or contact form below. We will reply from our person in charge.
In case
TEL: +81 29 - 896 - 9797 (weekdays 10: 00 ~ 17: 00)
FAX: +81 29 - 896 - 5676